Karmanos Cancer Institute
McLaren Greater Lansing
Lansing, MI
Not yet accepting
KER-050
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Growth Factor
- Phase 2
- Has results